DS 8500

Drug Profile

DS 8500

Alternative Names: DS-8500; DS-8500a

Latest Information Update: 23 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daiichi Sankyo Company
  • Class Antihyperglycaemics
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 2 diabetes mellitus

Most Recent Events

  • 11 Sep 2017 Efficacy, adverse events and pharmacokinetics data from a phase II trial in Type-2 diabetes mellitus presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
  • 01 May 2017 Discontinued - Phase-I for Type-2 diabetes mellitus (In volunteers) in USA (PO) due to unfavourable study results (Daiichi Sankyo pipeline, May 2017)
  • 01 May 2017 Discontinued - Phase-II for Type-2 diabetes mellitus in USA, Japan (PO) due to unfavourable study results (Daiichi Sankyo pipeline, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top